Kala names new chair
This article was originally published in Scrip
Executive Summary
Kala Pharmaceuticals, a developer of innovative ophthalmic products based on mucus-penetrating particle (MPP) technology, has appointed Mark Iwicki executive chair and a member of its board of directors. Mr Iwicki will help guide corporate strategy and commercial preparations for Kala's lead product candidate, KPI-121, a novel nanoparticle formulation of loteprednol etabonate in development for the treatment of post-surgical ocular inflammation and pain and for dry eye and meibomian gland disease. Prior to joining Kala, Mr Iwicki was president and CEO of Civitas Therapeutics, a company acquired by Acorda Therapeutics in 2014.